Placebo (Injection)

DRUG3 trials

Sponsors

Hoffmann-La Roche, Tonix Pharmaceuticals, Inc., Johns Hopkins University

Conditions

Binge Eating DisorderCocaine AbuseCocaine Adverse ReactionCocaine IntoxicationCocaine ToxicityCocaine UseObesity and OverweightUlcerative Colitis

Phase 2

Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)

TerminatedNCT06045793

Tonix Pharmaceuticals, Inc.Cocaine Abuse, Cocaine Adverse Reaction, Cocaine Intoxication +2

Start: 2024-08-16End: 2025-04-21Updated: 2025-06-24

Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder

RecruitingNCT06847399

Johns Hopkins UniversityBinge Eating Disorder, Obesity and Overweight

Start: 2025-09-17End: 2027-12-01Target: 105Updated: 2025-09-22

Phase 3

A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors

CompletedNCT02136069

Hoffmann-La RocheUlcerative Colitis

Start: 2014-12-24End: 2020-06-23Updated: 2021-12-03

Related Papers

P098 The Endoscopic Severity Score Map (ESSM): An Artificial Intelligence scoring system providing accurate, objective and localised measurements of endoscopic disease severity in ulcerative colitis

Journal of Crohn s and Colitis2024-01-01

P206 Artificial Intelligence reproduces central reading for automated scoring of colonoscopies from multiple clinical trials in Ulcerative Colitis

Journal of Crohn s and Colitis2023-01-30

Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.

2021-11-1778 citations

Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program.

2020-05-2269 citations

Antibodies to watch in 2020.

2020-01-01328 citations